GNPTAB

Across TCGA pan-cancer cohorts, GNPTAB mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated GNPTAB data layer compared with 23 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher GNPTAB mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated GNPTAB expression acts as an unfavorable survival marker.

CCRCC, GBM, and HNSC are the cancer types where GNPTAB mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Median	All	0.757	0.932	.003	50	view →
GBM	DFS	Median	All	0.601	0.835	<.001	38	view →
HNSC	DFS	Median	III,IV	0.905	1.000	.008	13	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

GNPTAB–CCRCC (OS)

Open the CCRCC breakdown →